Abstracts

A RANDOMIZED CONTROL TRIAL OF MHEALTH TOOL EFFECT ON VIRAL SUPPRESSION IN YOUTHS

Background: Adherence to antiretroviral therapy (ART) is the principal determinant for achieving and sustaining viral suppression, which decreases progression to AIDS, and reduces mortality and transmission risk. Whilst burden of HIV is increasing in adolescents and youth, adherence to medications, retention in care and self-management is still a challenge. It is important to evaluate if…

THE IMPACT OF PATIENT-CENTRED CARE ON HIV TREATMENT IN ZAMBIA: A STEPPED-WEDGE TRIAL

Background: Patient-provider interactions drive HIV-care retention. How to change HCW attitudes, communication, and practice is poorly understood. We evaluated a multicomponent patient centred care (PCC) intervention comprising HCW training, practice facilitation, and incentives, to improve patient-experience in Zambia. Methods: 24 clinics in Lusaka, Zambia, participated in a stepped wedge trial (August 2019-November 2021), over approximately…

D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE HIV THERAPY

Background: Randomised comparative data on efficacy and safety of second-line antiretroviral (ARV) regimens, after failure of non-nucleoside reverse transcriptase inhibitors (NNRTIs) across diverse geographical settings are limited. Methods: D2EFT is an international randomised open-label trial comparing dolutegravir (DTG) with ritonavir boosted darunavir (DRV/r) versus DTG with fixed tenofovir and lamivudine or emtricitabine (TDF/XTC) versus standard…

SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL

Background: Doravirine (DOR), an approved NNRTI, and islatravir (ISL), an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), have complementary mechanisms of action and resistance profiles. We report Week 48 results from a phase 3, non-inferiority trial (NCT04223791) evaluating a switch from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) to DOR/ISL (100/0.75mg), a once-daily single tablet regimen. Methods: Adults with…

SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL

Background: Doravirine (DOR), an approved NNRTI, and Islatravir (ISL), an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), have complementary mechanisms of action and resistance profiles. We report week 48 results from a phase 3, open-label, non-inferiority trial (P017, NCT04223778) evaluating a switch from oral combination ART to DOR/ISL (100/0.75mg), a once-daily single-tablet regimen. Methods: Virologically…

LOW CONCENTRATIONS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN PATIENTS WITH HIV

Background: Low cabotegravir and rilpivirine trough concentrations have been associated with virological failure in patients with HIV switching to long-acting cabotegravir and rilpivirine treatment in clinical trials. We wished to assess drug trough concentrations in patients initiating long-acting therapy. Methods: Starting in March 2022, we prospectively monitored all patients initiating long-acting cabotegravir and rilpivirine in…